Acadia (ACAD) delivered earnings and revenue surprises of -10.53% and 1.79%, respectively, for the quarter ended December ...

Full Year 2024 Results Key Financial Results Revenue: US$957.8m (up 32% from ...

Acadia is seeing solid growth from its two products on the market. Check out the analysis of ACAD stock following Q4 numbers ...

VP at Acadia Pharmaceuticals, pled guilty to insider trading, avoiding a $1.3M loss by illicitly selling shares ahead of a ...

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report)‘s stock had its “equal weight” rating reaffirmed by investment analysts at Morgan Stanley in a report issued on Friday,Benzinga reports. They ...

Morgan Stanley assumed coverage of Acadia Pharmaceuticals (ACAD) with an Equal Weight rating and $20 price target The firm sees patent ...

HC Wainwright reiterated their buy rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report ...

Analysts have set 12-month price targets for ACADIA Pharmaceuticals, revealing an average target of $25.0, a high estimate of $28.00, and a low estimate of $20.00. A 2.91% drop is evident in the ...

Acadia Pharmaceuticals (ACAD) and Saniona announced the completion of the two originally planned cohorts in their Phase 1 ...

Demos, a medical doctor who was the Vice President of Drug Safety and Pharmacovigilance and member of the drug label team at ...

Saniona (OMX: SANION), a clinical-stage biopharmaceutical company, today announces the appointment of Pierandrea Muglia, M.D., as Chief Medical Officer. Dr. Muglia brings more than 30 years of experie ...